| No recommendation (N=40) |
Recommendation (N=72) |
Overall (N=112) |
P-value | |
|---|---|---|---|---|
| Baseline age | ||||
| Mean (SD) | 76.1 (6.94) | 74.7 (14.2) | 75.2 (12.1) | 0.848 |
| Median [Min, Max] | 76.0 [63.0, 91.0] | 76.0 [0, 97.0] | 76.0 [0, 97.0] | |
| Missing | 1 (2.5%) | 1 (1.4%) | 2 (1.8%) | |
| Sex | ||||
| Female | 8 (20.0%) | 7 (9.7%) | 15 (13.4%) | 0.326 |
| Male | 31 (77.5%) | 62 (86.1%) | 93 (83.0%) | |
| Missing | 1 (2.5%) | 3 (4.2%) | 4 (3.6%) | |
| Race | ||||
| non-White | 2 (5.0%) | 6 (8.3%) | 8 (7.1%) | 0.882 |
| Unknown/NA | 4 (10.0%) | 11 (15.3%) | 15 (13.4%) | |
| White | 34 (85.0%) | 55 (76.4%) | 89 (79.5%) | |
| DBI group | ||||
| 0 | 23 (57.5%) | 14 (19.4%) | 37 (33.0%) | <0.001 |
| 0.01-0.99 | 12 (30.0%) | 21 (29.2%) | 33 (29.5%) | |
| 1+ | 5 (12.5%) | 37 (51.4%) | 42 (37.5%) | |
| Initial DBI | ||||
| Mean (SD) | 0.382 (0.548) | 1.21 (0.977) | 0.916 (0.936) | <0.001 |
| Median [Min, Max] | 0 [0, 2.08] | 1.00 [0, 3.90] | 0.700 [0, 3.90] | |
| 3-Month DBI | ||||
| Mean (SD) | 0.352 (0.586) | 1.07 (0.972) | 0.809 (0.918) | <0.001 |
| Median [Min, Max] | 0 [0, 2.20] | 0.890 [0, 3.90] | 0.700 [0, 3.90] | |
| Missing | 0 (0%) | 2 (2.8%) | 2 (1.8%) | |
| Provider type | ||||
| ARNP | 6 (15.0%) | 12 (16.7%) | 18 (16.1%) | 0.408 |
| PA | 3 (7.5%) | 0 (0%) | 3 (2.7%) | |
| Physician | 26 (65.0%) | 53 (73.6%) | 79 (70.5%) | |
| Unknown | 5 (12.5%) | 6 (8.3%) | 11 (9.8%) | |
| Missing | 0 (0%) | 1 (1.4%) | 1 (0.9%) | |
| Number of fall meds | ||||
| Mean (SD) | 3.15 (1.95) | 5.08 (2.58) | 4.40 (2.55) | <0.001 |
| Median [Min, Max] | 3.00 [0, 7.00] | 5.00 [1.00, 13.0] | 4.00 [0, 13.0] | |
| Missing | 1 (2.5%) | 1 (1.4%) | 2 (1.8%) | |
| Cardiovascular drug | ||||
| No | 12 (30.0%) | 11 (15.3%) | 23 (20.5%) | 0.181 |
| Yes | 28 (70.0%) | 61 (84.7%) | 89 (79.5%) | |
| Hypoglycemic drug | ||||
| No | 33 (82.5%) | 51 (70.8%) | 84 (75.0%) | 0.393 |
| Yes | 7 (17.5%) | 21 (29.2%) | 28 (25.0%) | |
| Opioid | ||||
| No | 36 (90.0%) | 59 (81.9%) | 95 (84.8%) | 0.523 |
| Yes | 4 (10.0%) | 13 (18.1%) | 17 (15.2%) | |
| Anticonvulsant drug | ||||
| No | 31 (77.5%) | 43 (59.7%) | 74 (66.1%) | 0.163 |
| Yes | 9 (22.5%) | 29 (40.3%) | 38 (33.9%) | |
| Anticholinergic | ||||
| No | 30 (75.0%) | 43 (59.7%) | 73 (65.2%) | 0.267 |
| Yes | 10 (25.0%) | 29 (40.3%) | 39 (34.8%) | |
| Sedative/hypnotic drug | ||||
| No | 38 (95.0%) | 59 (81.9%) | 97 (86.6%) | 0.151 |
| Yes | 2 (5.0%) | 13 (18.1%) | 15 (13.4%) | |
| Muscle relaxer | ||||
| No | 39 (97.5%) | 60 (83.3%) | 99 (88.4%) | 0.0809 |
| Yes | 1 (2.5%) | 12 (16.7%) | 13 (11.6%) | |
| Antidepressant | ||||
| No | 33 (82.5%) | 33 (45.8%) | 66 (58.9%) | <0.001 |
| Yes | 7 (17.5%) | 39 (54.2%) | 46 (41.1%) | |
| Other drug | ||||
| No | 35 (87.5%) | 53 (73.6%) | 88 (78.6%) | 0.229 |
| Yes | 5 (12.5%) | 19 (26.4%) | 24 (21.4%) |
| Recommendation not performed (N=35) |
Recommendation performed (N=37) |
Overall (N=72) |
P-value | |
|---|---|---|---|---|
| Baseline age | ||||
| Mean (SD) | 75.3 (14.9) | 74.2 (13.6) | 74.7 (14.2) | 0.953 |
| Median [Min, Max] | 76.0 [0, 97.0] | 75.0 [0, 92.0] | 76.0 [0, 97.0] | |
| Missing | 1 (2.9%) | 0 (0%) | 1 (1.4%) | |
| Sex | ||||
| Female | 3 (8.6%) | 4 (10.8%) | 7 (9.7%) | 0.962 |
| Male | 30 (85.7%) | 32 (86.5%) | 62 (86.1%) | |
| Missing | 2 (5.7%) | 1 (2.7%) | 3 (4.2%) | |
| Race | ||||
| non-White | 3 (8.6%) | 3 (8.1%) | 6 (8.3%) | 0.995 |
| Unknown/NA | 6 (17.1%) | 5 (13.5%) | 11 (15.3%) | |
| White | 26 (74.3%) | 29 (78.4%) | 55 (76.4%) | |
| NumberRecommendationsMade | ||||
| Mean (SD) | 1.97 (1.22) | 1.84 (1.21) | 1.90 (1.21) | 0.897 |
| Median [Min, Max] | 2.00 [1.00, 6.00] | 2.00 [1.00, 7.00] | 2.00 [1.00, 7.00] | |
| NumberReccomendationsAccepted | ||||
| Mean (SD) | 0 (0) | 1.43 (1.07) | 0.736 (1.05) | <0.001 |
| Median [Min, Max] | 0 [0, 0] | 1.00 [1.00, 7.00] | 1.00 [0, 7.00] | |
| Initial DBI | ||||
| Mean (SD) | 1.32 (0.965) | 1.11 (0.992) | 1.21 (0.977) | 0.668 |
| Median [Min, Max] | 1.10 [0, 3.90] | 0.860 [0, 3.30] | 1.00 [0, 3.90] | |
| 3-Month DBI | ||||
| Mean (SD) | 1.32 (0.975) | 0.835 (0.922) | 1.07 (0.972) | 0.112 |
| Median [Min, Max] | 1.05 [0, 3.90] | 0.685 [0, 3.30] | 0.890 [0, 3.90] | |
| Missing | 1 (2.9%) | 1 (2.7%) | 2 (2.8%) | |
| Provider type | ||||
| ARNP | 6 (17.1%) | 6 (16.2%) | 12 (16.7%) | 0.967 |
| Physician | 26 (74.3%) | 27 (73.0%) | 53 (73.6%) | |
| Unknown | 2 (5.7%) | 4 (10.8%) | 6 (8.3%) | |
| Missing | 1 (2.9%) | 0 (0%) | 1 (1.4%) | |
| Cardiovascular drug | ||||
| No | 6 (17.1%) | 5 (13.5%) | 11 (15.3%) | 0.913 |
| Yes | 29 (82.9%) | 32 (86.5%) | 61 (84.7%) | |
| Hypoglycemic drug | ||||
| No | 24 (68.6%) | 27 (73.0%) | 51 (70.8%) | 0.919 |
| Yes | 11 (31.4%) | 10 (27.0%) | 21 (29.2%) | |
| Opioid | ||||
| No | 27 (77.1%) | 32 (86.5%) | 59 (81.9%) | 0.588 |
| Yes | 8 (22.9%) | 5 (13.5%) | 13 (18.1%) | |
| Anticonvulsant drug | ||||
| No | 20 (57.1%) | 23 (62.2%) | 43 (59.7%) | 0.91 |
| Yes | 15 (42.9%) | 14 (37.8%) | 29 (40.3%) | |
| Anticholinergic | ||||
| No | 22 (62.9%) | 21 (56.8%) | 43 (59.7%) | 0.87 |
| Yes | 13 (37.1%) | 16 (43.2%) | 29 (40.3%) | |
| Sedative/hypnotic drug | ||||
| No | 29 (82.9%) | 30 (81.1%) | 59 (81.9%) | 0.981 |
| Yes | 6 (17.1%) | 7 (18.9%) | 13 (18.1%) | |
| Muscle relaxer | ||||
| No | 30 (85.7%) | 30 (81.1%) | 60 (83.3%) | 0.87 |
| Yes | 5 (14.3%) | 7 (18.9%) | 12 (16.7%) | |
| Antidepressant | ||||
| No | 13 (37.1%) | 20 (54.1%) | 33 (45.8%) | 0.355 |
| Yes | 22 (62.9%) | 17 (45.9%) | 39 (54.2%) | |
| Other drug | ||||
| No | 26 (74.3%) | 27 (73.0%) | 53 (73.6%) | 0.992 |
| Yes | 9 (25.7%) | 10 (27.0%) | 19 (26.4%) |
| DBI not provided (N=25) |
DBI provided (N=47) |
P-value | |
|---|---|---|---|
| NumberRecommendationsMade | |||
| Mean (SD) | 1.56 (0.768) | 2.09 (1.36) | 0.0404 |
| Median [Min, Max] | 1.00 [1.00, 4.00] | 2.00 [1.00, 7.00] | |
| NumberReccomendationsAccepted | |||
| Mean (SD) | 0.840 (0.688) | 0.681 (1.20) | 0.477 |
| Median [Min, Max] | 1.00 [0, 2.00] | 0 [0, 7.00] | |
| DBI group | |||
| 0 | 4 (16.0%) | 10 (21.3%) | 0.336 |
| 0.01-0.99 | 10 (40.0%) | 11 (23.4%) | |
| 1+ | 11 (44.0%) | 26 (55.3%) | |
| Initial DBI | |||
| Mean (SD) | 0.970 (0.729) | 1.34 (1.07) | 0.087 |
| Median [Min, Max] | 0.800 [0, 2.50] | 1.20 [0, 3.90] | |
| 3-Month DBI | |||
| Mean (SD) | 0.777 (0.749) | 1.21 (1.04) | 0.0498 |
| Median [Min, Max] | 0.760 [0, 2.60] | 1.00 [0, 3.90] | |
| Missing | 2 (8.0%) | 0 (0%) | |
| Baseline age | |||
| Mean (SD) | 76.6 (5.61) | 73.7 (17.1) | 0.296 |
| Median [Min, Max] | 75.0 [69.0, 92.0] | 76.0 [0, 97.0] | |
| Missing | 0 (0%) | 1 (2.1%) |
| N | Fall meds taken | Recs made | Recs accepted | Proportion w/ recs accepted | Proportion of recs accepted | |
|---|---|---|---|---|---|---|
| Overall | ||||||
| Overall | 72 | 5.1 | 1.9 | 0.7 | 51.4 | 43.4 |
| Was DBI provided? | ||||||
| DBI not provided | 25 | 5.1 | 1.6 | 0.8 | 68.0 | 61.3 |
| DBI provided | 47 | 5.1 | 2.1 | 0.7 | 42.6 | 33.9 |
| DBI group | ||||||
| 0 | 14 | 2.7 | 1.3 | 0.9 | 71.4 | 67.9 |
| 0.01-0.99 | 21 | 3.9 | 1.4 | 0.5 | 47.6 | 40.5 |
| 1+ | 37 | 6.6 | 2.4 | 0.8 | 45.9 | 35.8 |
| Number of recs | ||||||
| 1 | 34 | 4.1 | 1.0 | 0.5 | 52.9 | 52.9 |
| 2 | 24 | 5.0 | 2.0 | 0.8 | 54.2 | 41.7 |
| 3 | 6 | 7.5 | 3.0 | 0.5 | 50.0 | 16.7 |
| 4 | 6 | 7.3 | 4.0 | 0.8 | 33.3 | 20.8 |
| 6 | 1 | 9.0 | 6.0 | 0.0 | 0.0 | 0.0 |
| 7 | 1 | 7.0 | 7.0 | 7.0 | 100.0 | 100.0 |
| N | Fall meds taken | Recs made | Recs accepted | Proportion w/ recs accepted | Proportion of recs accepted | |
|---|---|---|---|---|---|---|
| Overall | ||||||
| Overall | 25 | 5.1 | 1.6 | 0.8 | 68.0 | 61.3 |
| DBI group | ||||||
| 0 | 4 | 3.5 | 1.2 | 1.2 | 100.0 | 100.0 |
| 0.01-0.99 | 10 | 3.8 | 1.4 | 0.8 | 70.0 | 60.0 |
| 1+ | 11 | 6.9 | 1.8 | 0.7 | 54.5 | 48.5 |
| N | Fall meds taken | Recs made | Recs accepted | Proportion w/ recs accepted | Proportion of recs accepted | |
|---|---|---|---|---|---|---|
| Overall | ||||||
| Overall | 47 | 5.1 | 2.1 | 0.7 | 42.6 | 33.9 |
| DBI group | ||||||
| 0 | 10 | 2.3 | 1.3 | 0.7 | 60.0 | 55.0 |
| 0.01-0.99 | 11 | 3.9 | 1.5 | 0.3 | 27.3 | 22.7 |
| 1+ | 26 | 6.5 | 2.7 | 0.8 | 42.3 | 30.4 |
| N | Fall meds taken | Recs made | Recs accepted | Proportion w/ recs accepted | Proportion of recs accepted | |
|---|---|---|---|---|---|---|
| Overall | ||||||
| Overall | 72 | 5.1 | 1.9 | 0.7 | 51.4 | 43.4 |
| Cardiovascular drug | ||||||
| No | 11 | 3.2 | 1.8 | 0.5 | 45.5 | 30.3 |
| Yes | 61 | 5.4 | 1.9 | 0.8 | 52.5 | 45.8 |
| Hypoglycemic drug | ||||||
| No | 51 | 4.2 | 1.8 | 0.8 | 52.9 | 46.7 |
| Yes | 21 | 7.3 | 2.1 | 0.7 | 47.6 | 35.3 |
| Opioid | ||||||
| No | 59 | 4.7 | 1.8 | 0.8 | 54.2 | 46.5 |
| Yes | 13 | 6.9 | 2.5 | 0.5 | 38.5 | 29.5 |
| Anticonvulsant drug | ||||||
| No | 43 | 4.4 | 1.6 | 0.7 | 53.5 | 45.7 |
| Yes | 29 | 6.1 | 2.4 | 0.9 | 48.3 | 39.9 |
| Anticholinergic | ||||||
| No | 43 | 4.6 | 1.9 | 0.8 | 48.8 | 44.4 |
| Yes | 29 | 5.7 | 2.0 | 0.7 | 55.2 | 42.0 |
| Sedative/hypnotic drug | ||||||
| No | 59 | 4.8 | 1.8 | 0.7 | 50.8 | 43.1 |
| Yes | 13 | 6.5 | 2.2 | 1.0 | 53.8 | 44.9 |
| Muscle relaxer | ||||||
| No | 60 | 4.7 | 1.7 | 0.7 | 50.0 | 43.9 |
| Yes | 12 | 6.8 | 2.9 | 1.0 | 58.3 | 41.0 |
| Antidepressant | ||||||
| No | 33 | 3.8 | 1.5 | 0.7 | 60.6 | 51.5 |
| Yes | 39 | 6.1 | 2.2 | 0.7 | 43.6 | 36.5 |
| Other drug | ||||||
| No | 53 | 4.9 | 1.8 | 0.7 | 50.9 | 43.7 |
| Yes | 19 | 5.5 | 2.2 | 0.8 | 52.6 | 42.5 |
## # A tibble: 116 × 2
## Drug Count
## <chr> <dbl>
## 1 amlodipine 33
## 2 metoprolol 28
## 3 losartan 28
## 4 tamsulosin 28
## 5 gabapentin 25
## 6 lisinopril 23
## 7 trazodone 13
## 8 carvedilol 11
## 9 duloxetine 10
## 10 cetirizine 10
## # ℹ 106 more rows
## # A tibble: 75 × 2
## Drug Count
## <chr> <dbl>
## 1 gabapentin 25
## 2 trazodone 13
## 3 duloxetine 10
## 4 cetirizine 10
## 5 loratadine 10
## 6 sertraline 9
## 7 bupropion 9
## 8 oxycodone 8
## 9 pregabalin 7
## 10 venlafaxine 7
## # ℹ 65 more rows
| N | DBI | Recs made | Recs accepted | Proportion w/ recs accepted | Proportion of recs accepted | |
|---|---|---|---|---|---|---|
| Overall | ||||||
| NA | 72 | 1.2 | 1.9 | 0.7 | 51.4 | 43.4 |
| Gabapentin | ||||||
| No | 53 | 1.0 | 1.7 | 0.6 | 49.1 | 41.8 |
| Yes | 19 | 1.8 | 2.6 | 1.1 | 57.9 | 47.8 |
| Trazodone | ||||||
| No | 61 | 1.1 | 1.9 | 0.7 | 50.8 | 42.5 |
| Yes | 11 | 1.8 | 2.2 | 1.1 | 54.5 | 48.5 |
| Loratadine | ||||||
| No | 67 | 1.2 | 1.9 | 0.7 | 50.7 | 43.2 |
| Yes | 5 | 1.0 | 2.2 | 0.8 | 60.0 | 46.7 |
| Duloxetine | ||||||
| No | 63 | 1.1 | 1.8 | 0.8 | 54.0 | 45.9 |
| Yes | 9 | 1.9 | 2.4 | 0.4 | 33.3 | 25.9 |
| Cetirizine | ||||||
| No | 65 | 1.2 | 1.9 | 0.7 | 49.2 | 41.2 |
| Yes | 7 | 0.9 | 1.6 | 0.9 | 71.4 | 64.3 |
| Glipizide/Glimeperide | ||||||
| No | 70 | 1.2 | 1.9 | 0.8 | 52.9 | 44.6 |
| Yes | 2 | 1.1 | 1.0 | 0.0 | 0.0 | 0.0 |
##
## Call:
## glm(formula = rec_performed_bi_n ~ AgeAtEnrollment + dbi_group +
## dbi_provided, family = binomial, data = dbi_rec)
##
## Coefficients:
## Estimate Std. Error z value Pr(>|z|)
## (Intercept) 5.62537 3.79619 1.482 0.1384
## AgeAtEnrollment -0.06469 0.04747 -1.363 0.1729
## dbi_group0 1.42810 0.80579 1.772 0.0763 .
## dbi_group1+ -0.14556 0.63459 -0.229 0.8186
## dbi_providedDBI provided -1.17479 0.56220 -2.090 0.0367 *
## ---
## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
##
## (Dispersion parameter for binomial family taken to be 1)
##
## Null deviance: 95.524 on 68 degrees of freedom
## Residual deviance: 86.073 on 64 degrees of freedom
## AIC: 96.073
##
## Number of Fisher Scoring iterations: 4
##
## Call:
## glm(formula = rec_performed_bi_n ~ AgeAtEnrollment + dbi_group +
## dbi_provided + dbi_group * dbi_provided, family = binomial,
## data = dbi_rec)
##
## Coefficients:
## Estimate Std. Error z value Pr(>|z|)
## (Intercept) 5.89258 3.96526 1.486 0.1373
## AgeAtEnrollment -0.06315 0.04863 -1.298 0.1941
## dbi_group0 16.48248 1950.22368 0.008 0.9933
## dbi_group1+ -1.02521 0.97542 -1.051 0.2932
## dbi_providedDBI provided -1.93225 0.98684 -1.958 0.0502 .
## dbi_group0:dbi_providedDBI provided -14.88472 1950.22393 -0.008 0.9939
## dbi_group1+:dbi_providedDBI provided 1.49237 1.23577 1.208 0.2272
## ---
## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
##
## (Dispersion parameter for binomial family taken to be 1)
##
## Null deviance: 95.524 on 68 degrees of freedom
## Residual deviance: 83.477 on 62 degrees of freedom
## AIC: 97.477
##
## Number of Fisher Scoring iterations: 16
##
## Call:
## lm(formula = dbi_diff ~ AgeAtEnrollment + dbi_group + dbi_provided,
## data = dbi_rec_performed)
##
## Residuals:
## Min 1Q Median 3Q Max
## -0.69594 -0.19307 -0.01757 0.15092 0.69611
##
## Coefficients:
## Estimate Std. Error t value Pr(>|t|)
## (Intercept) 0.536000 1.019101 0.526 0.603
## AgeAtEnrollment -0.004048 0.012802 -0.316 0.754
## dbi_group0 -0.160655 0.157785 -1.018 0.317
## dbi_group1+ 0.162033 0.168557 0.961 0.344
## dbi_providedDBI provided -0.094563 0.122514 -0.772 0.446
##
## Residual standard error: 0.3427 on 30 degrees of freedom
## (1 observation deleted due to missingness)
## Multiple R-squared: 0.1811, Adjusted R-squared: 0.07196
## F-statistic: 1.659 on 4 and 30 DF, p-value: 0.1855
##
## Call:
## lm(formula = dbi_diff ~ AgeAtEnrollment + dbi_group * dbi_provided,
## data = dbi_rec_performed)
##
## Residuals:
## Min 1Q Median 3Q Max
## -0.72727 -0.23215 -0.00686 0.13989 0.69730
##
## Coefficients:
## Estimate Std. Error t value Pr(>|t|)
## (Intercept) 0.803926 1.102570 0.729 0.472
## AgeAtEnrollment -0.006865 0.013707 -0.501 0.620
## dbi_group0 -0.282193 0.226093 -1.248 0.222
## dbi_group1+ 0.095331 0.222550 0.428 0.672
## dbi_providedDBI provided -0.244085 0.243875 -1.001 0.325
## dbi_group0:dbi_providedDBI provided 0.274977 0.343853 0.800 0.431
## dbi_group1+:dbi_providedDBI provided 0.155534 0.309351 0.503 0.619
##
## Residual standard error: 0.3507 on 28 degrees of freedom
## (1 observation deleted due to missingness)
## Multiple R-squared: 0.1995, Adjusted R-squared: 0.02801
## F-statistic: 1.163 on 6 and 28 DF, p-value: 0.3535